ANCA Associated Vasculitis Subtypes: Response [Letter] за авторством Merkel PA, Jayne DRW, Bekker P

Отримати повний текст

PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease за авторством Bekker, P, Keshav, S, Johnson, D, Schall, T

PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Diseas... за авторством Keshav, S, Johnson, D, Bekker, P, Schall, T

Traficet-EN, an Oral CCR9-Specific Antagonist, induces high levels of remission in the open-label Phase of PROTECT-1 in Crohn's Disease за авторством Bekker, P, Johnson, D, Hamilton, G, Keshav, S, Schall, T

Traficet-EN, an oral CCR9-specific antagonist, induces high levels of remission in the open-label phase of PROTECT-1 in Crohn's disease за авторством Bekker, P, Hamilton, G, Johnson, D, Keshav, S, Schall, T

Pharmacological inhibition of CCR9 is a novel approach in the treatment of inflammatory bowel disease за авторством Bekker, P, Keshav, S, Wei, Z, Ertl, L, Wang, Y, Lai, N, Wright, J, Ungashe, S, Schall, T

Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease за авторством Bekker, P, Velde, A, Pronk, I, Keshav, S, Hommes, D, Hanauer, S, Ungashe, S, Zheng, W, Wright, K, Schall, T

Protect-1, a prospective randomized oral therapy evaluation of CCX282-B (Traficet-EN) in Crohn's disease trial за авторством Bekker, P, Petryka, R, Vanasek, T, Niv, Y, Marlicz, K, Haagen-Nielsen, O, Dahelrup, J, Dotan, I, Compel, V, Keshav, S, Schall, T

PROTECT-1: A prospective randomized trial of CCX282-B (Traficet-EN), a novel oral therapy targeting chemokine receptor 9 in Crohn's disease за авторством Keshav, S, Petryka, R, Vanask, T, Niv, Y, Marlicz, K, Haagen-Nielsen, O, Machado, M, Dahlerup, J, Schreiber, S, Bekker, P, Sankar, S, Schall, T

Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. за авторством Walters, M, Wang, Y, Lai, N, Baumgart, T, Zhao, B, Dairaghi, D, Bekker, P, Ertl, L, Penfold, M, Jaen, J, Keshav, S, Wendt, E, Pennell, A, Ungashe, S, Wei, Z, Wright, J, Schall, T

MEDI 167-Discovery of the highly potent, selective and orally bioavailable CCR9 antagonist CCX282-B за авторством Ungashe, S, Wei, Z, Rubas, W, Lai, N, Ertl, L, Baumgart, T, Wang, H, Miao, Z, Hor, S, Premack, B, Moore, J, Sullivan, E, Pennell, A, Keshav, S, Sanders, M, Howard, M, Wright, J, Bekker, P, Schall, T